Utilizing technology transferred from Cornell University, Aegen Biosciences creates next generation tools for toxicology, drug discovery, drug development, genomics, pharmacogenomics and clinical diagnostics. Aegen is developing an animal-on-a-chip device based on technology invented at Cornell. Commercialization of the technology has the potential to increase the success rates and decrease the development time of marketable drugs, while greatly reducing the number of animals used during preclinical studies.
